HSR26-243: Real-World Persistence With CDK4/6 Inhibitors in Early and Metastatic HR-Positive, HER2-Negative Breast Cancer
Journal of the National Comprehensive Cancer Network · 31.03.2026 · 24 (3.5)
DOI: 10.6004/jnccn.2025.7322 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, erschienen am 31.03.2026. Verfasst von Guannan Gong und 10 weiteren Autor:innen. Beteiligte Einrichtung: 1Yale University, New Haven, CT.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- 1Yale University, New Haven, CT.
- 2Yale Cancer Center, New Haven, CT.
- 3University of Rhode Island, Kingston, RI.
- 4Yale New Haven Health, New Haven, CT.
Zitieren
APA
Gong, G., Brown, B. R., Pandya, S., Caetano, M., Legare, R., Taghzout, S., Ramos, M., Liu, J., Hood, A., Zummo, M., & Lustberg, M. (2026). HSR26-243: Real-World Persistence With CDK4/6 Inhibitors in Early and Metastatic HR-Positive, HER2-Negative Breast Cancer. Journal of the National Comprehensive Cancer Network, 24(3.5). https://doi.org/10.6004/jnccn.2025.7322
Vancouver
Gong G, Brown BR, Pandya S, Caetano M, Legare R, Taghzout S, et al. HSR26-243: Real-World Persistence With CDK4/6 Inhibitors in Early and Metastatic HR-Positive, HER2-Negative Breast Cancer. Journal of the National Comprehensive Cancer Network. 2026;24(3.5). doi:10.6004/jnccn.2025.7322
BibTeX
@article{Gong2026,
author = {Gong, Guannan and Brown, Britny R and Pandya, Sameer and Caetano, Michelle and Legare, Robert and Taghzout, Salma and Ramos, Mariah and Liu, Jessica and Hood, Annette and Zummo, Michael and Lustberg, Maryam},
title = {HSR26-243: Real-World Persistence With CDK4/6 Inhibitors in Early and Metastatic HR-Positive, HER2-Negative Breast Cancer},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2026},
volume = {24},
number = {3.5},
doi = {10.6004/jnccn.2025.7322}
}
EUVIMED